Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16592752 | 0.87 | NPC1 (0.58) | S1PR1S1PR3NPC1RAB9ACHRNB2 | |
| SCHEMBL13991227 | 0.83 | NPC1 (0.59) | S1PR1S1PR3NPC1RAB9AMAPT | |
| SCHEMBL3082641 | 0.82 | S1PR1 (0.73) | S1PR1S1PR3NPC1RAB9ANFKB1 | |
| SCHEMBL4618489 | 0.82 | AKR1C3 (0.48) | S1PR1S1PR3NPC1RAB9AAKR1C3 | |
| SCHEMBL16592426 | 0.82 | NPC1 (0.76) | S1PR1NPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL11715801 | 0.82 | NPC1 (0.76) | S1PR1NPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL26093326 | 0.81 | NR1H4 (0.63) | S1PR1NPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL11480733 | 0.78 | RAB9A (0.65) | S1PR1NPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL4617232 | 0.78 | S1PR1 (0.78) | S1PR1S1PR3MEN1KMT2ACYP1A2 | |
| SCHEMBL13417080 | 0.78 | S1PR1 (0.78) | S1PR1S1PR3NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233473-A1 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1981858-B1 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090137636-A1 | Reverse Isoxazoles | NOVARTIS AG | 2009-05-28 | — | — | US | disclosed |
| US-20090137636-A1 | Reverse Isoxazoles | NOVARTIS AG | 2009-05-28 | — | — | US | disclosed |
| CN-101374821-A | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1981858-A2 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | Novartis AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1893591-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007085451-A2 | 3,5-DI (ARYL OR HETEROARYL) ISOXAZOLES AND 1, 2, 4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI -INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006131336-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137636-A1 | Reverse Isoxazoles | CYP3A7, CYP3A4, TBXA2R | S1PR1 3804/4885S1PR3 2578/4885NPC1 1311/4885 |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | S1PR1 13/4885S1PR3 22/4885NPC1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.